Livanova
LIVN
Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them
Value held
$0k
Combined value at quarter end
Last quarter
0 bought
1 sold or trimmed
Price at Q3 ’24 end
$52.54
-4.2% in the quarter
Share price change by quarter
+9.4%Q4 ’22
-21.5%Q1 ’23
+18.0%Q2 ’23
+2.8%Q3 ’23
-2.2%Q4 ’23
+8.1%Q1 ’24
-2.0%Q2 ’24
-4.2%Q3 ’24
Managers holding it, by quarter
1Q4 ’23
1Q1 ’24
1Q2 ’24
1Q3 ’24
1Q4 ’24
1Q1 ’25
1Q2 ’25
0Q3 ’25
0Q4 ’25
1Q1 ’26
0Q2 ’26
0Q3 ’26
Who holds it
No manager on this site held it in their latest 13F.
Sold out last quarter
- Maverick Capital in Q2 2026
Directors buying and selling
How this works
| Bought or sold | ||||
|---|---|---|---|---|
| 10 Sep 2026 | Bianchi FrancescoDirector | ▼ Sold | 3,500 | $273k |
| 4 Sep 2026 | Story BrookeDirector | ▼ Sold | 2,300 | $187k |
| 31 Aug 2026 | Bianchi FrancescoDirector | ▼ Sold | 1,650 | $132k |
| 11 Aug 2026 | Tezel AhmetChief Innovation Officer | ▼ Sold | 2,675 | $208k |
About the company
- Sector
- Health care · Electromedical & Electrotherapeutic Apparatus
- Incorporated in
- United Kingdom
- Financial year ends
- 31 December
- Shares outstanding
- 55m at 29 Jul 2026
- SEC filings
- Annual reports and other filings on EDGAR
Revenue and profit
$282mApr ’14
$292mApr ’15
$965m2016
$1.0bn2017
$1.1bn2018
$1.1bn2019
$934m2020
$1.0bn2021
$1.0bn2022
$1.2bn2023
$1.3bn2024
$1.4bn2025
| Year | Revenue | Net income |
|---|---|---|
| 2025 | $1.4bn | −$243m |
| 2024 | $1.3bn | $63.2m |
| 2023 | $1.2bn | $17.6m |
| 2022 | $1.0bn | −$86.2m |
| 2021 | $1.0bn | −$136m |
| 2020 | $934m | −$349m |
| 2019 | $1.1bn | −$158m |
| 2018 | $1.1bn | −$189m |
| 2017 | $1.0bn | −$25.1m |
| 2016 | $965m | −$62.8m |
| Year to Apr 2015 | $292m | $57.8m |
| Year to Apr 2014 | $282m | $54.9m |